Previous Close | 5.30 |
Open | 5.35 |
Bid | 5.38 x 0 |
Ask | 5.41 x 0 |
Day's Range | 5.32 - 5.44 |
52 Week Range | 4.28 - 5.75 |
Volume | |
Avg. Volume | 69,415 |
Market Cap | 561.462M |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.06 |
Earnings Date | Mar 21, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.56 |
Will release its fourth-quarter and year-end 2023 financial results on Thursday, March 21, prior to ...
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 21, 2024 Time: 8:30 a.m. ET Telephone: Toll
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...